Drug Profile
Research programme: cancer therapeutics - Acropolis Pharmaceuticals
Alternative Names: PA-105Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Acropolis Pharmaceuticals
- Class Small molecules
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Protein synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA
- 17 May 2007 Preclinical trials in Prostate cancer in USA (unspecified)
- 17 May 2007 Data presented at the 98th Annual Meeting of the American Association for Cancer Research (AACR-2007) added to the Cancer pharmacodynamics section